Introduction
============

*Acinetobacter baumannii* is a lactose non-fermenting gram-negative bacillus (NF-GNB) that has emerged as a highly troublesome pathogen particularly in critically ill patients.[@b1-mjhid-10-1-e2018044] Clinical isolates of *A. baumannii* are responsible for pulmonary, device-related, bloodstream, and urinary tract infections and are frequently isolated from hospitalized ICU patients.[@b2-mjhid-10-1-e2018044] These isolates were associated with multiple antibiotic resistance, and the spread of drug-resistant *A. baumannii* strains among hospitalized patients have become an increasing public health threat.[@b3-mjhid-10-1-e2018044],[@b4-mjhid-10-1-e2018044] Furthermore, due to the intrinsic resistance mechanisms in this opportunistic nosocomial pathogen, it is quicker to become multidrug-resistant (MDR).[@b5-mjhid-10-1-e2018044]

Polymyxin B and polymyxin E (colistin), are an increasingly significant part of the antimicrobial agents against MDR gram-negative bacteria. These two drugs have the same spectrum and are appropriate for use in the clinical settings.[@b6-mjhid-10-1-e2018044],[@b7-mjhid-10-1-e2018044] At present in Europe in the patients with MDR *A. baumannii* the clinician utilize the colistin, and in the future, it is possible using the new derivatives.[@b8-mjhid-10-1-e2018044]

Aminoglycosides are used most commonly in the treatment of life-threatening infections caused by *A. baumannii* strains.[@b9-mjhid-10-1-e2018044] The efflux pumps, decreased outer membrane permeability, amino acid substitutions and enzymatic modification, are the main mechanisms of aminoglycoside resistance in these bacteria.[@b10-mjhid-10-1-e2018044] Enzymatic modification is the most common type of aminoglycoside resistance in *A. baumannii* clinical isolates and usually results in high-level drug resistance.[@b11-mjhid-10-1-e2018044] Most enzyme-mediated resistance in *A. baumannii* is due to the genes encoding for aminoglycoside-modifying enzymes (AMEs) which found on plasmids and transposons. Three types of AMEs include N-acetyltransferases (AAC), O-adenyltransferases (ANT), and O-phosphotransferases (APH).[@b12-mjhid-10-1-e2018044],[@b13-mjhid-10-1-e2018044]

The plasmid-mediated quinolone resistance (PMQR) genes, such as *qnrA, qnrB, and qnrS*, are responsible for quinolone resistance in *A. baumannii* isolates. PMQRs were first detected in the 1990s as a plasmid gene in *Klebsiella pneumonia* clinical isolates. Subsequent studies have shown that *qnr* genes have a worldwide distribution in a range of Gram-negative opportunist pathogens. Although the *qnr* expression mechanism which confers clinical quinolone resistance is the least understood, the DNA topoisomerase protection protein Qnr protects DNA from quinolone binding and causes resistance to quinolones.[@b14-mjhid-10-1-e2018044]--[@b16-mjhid-10-1-e2018044] The prevalence of quinolone- and/or aminoglycoside-resistant *A. baumannii* was increased during the past decade. The present study was carried out to investigate antibiotic resistance pattern and resistance-related genes such as *qnrA, anrB, qnrS, aac(3)-IIa,* and *aac(6′)-Ib* in *A. baumannii* clinical isolates by polymerase chain reaction (PCR) assay.

Materials and Methods
=====================

The current study was a cross-sectional descriptive research which conducted from February 2015 to April 2016, at two teaching hospitals (Baqiyatallah and Moheb mehr hospitals) in Tehran, Iran. One hundred non-repetitive strains of *A. baumannii* were obtained from different clinical specimens, including tracheal secretion, blood, wound, urine, and other samples. The isolates were identified using well-recognized biochemical tests such as Gram staining, oxidative/fermentative glucose test, catalase test, motility, oxidase test, citrate utilization, and capability to grow at 42--44°C.[@b17-mjhid-10-1-e2018044] Species identification was confirmed by detection of *blaOXA-51-like* genes, as described previously.[@b18-mjhid-10-1-e2018044] All strains were preserved in Luria--Bertani broth (Merck Co., Germany) containing 20% glycerol (v/v) at −80°C for further use.

Antimicrobial susceptibility was carried out on the Mueller-Hinton agar plates (Merck Co., Germany) using the Kirby--Bauer (KB) method as suggested by the Clinical and Laboratory Standards Institute guideline (CLSI document M100-S14).

The antimicrobial agents were as follows: meropenem (10 μg), gentamicin (10 μg), amikacin (30 μg), imipenem (10 μg), tobramycin (10 μg), tetracycline (30 μg), piperacillin-tazobactam (100--10 μg), cefepime (30 μg), ceftriaxone (30 μg), ampicillin-sulbactam (10--10 μg), and polymyxin B (300 μg) (MAST Diagnostics, Merseyside, UK). Multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) isolates were detected according to the instruction suggested by the Centers for Disease Control and Prevention (CDC). *Escherichia coli* ATCC 25922 and *Acinetobacter baumannii* ATCC 19606 were used as negative and positive controls, respectively.

Genomic DNA was extracted from *A. baumannii* colonies grown overnight on blood agar by Bioneer Co., Korea Kit and used as a template for PCR assay. PCR amplification was done to detect aminoglycoside-(*aac(3)-IIa and aac(6′)-Ib*) and quinolone-(*qnrA, qnrB, and qnrS)* related resistance genes. Amplification of AME and PMQR genes was carried out using a thermal gradient cycler (Eppendorf Co., Germany) with the following protocol: 5 minutes at 94° C for the initial denaturation and 36 cycles of amplification consisting of 45 seconds at 94°C, 45 seconds at 52--58°C, and 45 seconds at 72°C, with 5 minutes at 72°C for the final extension. The specific primers, temperatures of annealing, and amplicons size used for PCR are detailed in [Table 1](#t1-mjhid-10-1-e2018044){ref-type="table"}.

The current survey was a descriptive research. The MINITAB16 software was used for statistical analyses. The P value and confidence intervals were ≤0.05 and 95%, respectively.

Results
=======

One hundred isolates of *A. baumannii* were obtained from different clinical specimens. The samples included blood (n=40, 40%), tracheal secretion (n=27, 27%), wound (n=12, 12%), urine (n=8, 8%), and unknown (n=13, 13%) specimens isolated from hospitalized patients in ICU (n=40, 40%), emergency department (n=20, 20%), and infectious disease department (30, 30%), and other departments (n=10, 10%).

The resistance percentage of meropenem, gentamicin, amikacin, imipenem, tobramycin, tetracycline, piperacillin-tazobactam, cefepime, ceftriaxone, ampicillin-sulbactam and polymyxin B were 69%, 82%, 63%, 74%, 56%, 51%, 70%, 97%, 95%, 49%, 3%, respectively ([Table 2](#t2-mjhid-10-1-e2018044){ref-type="table"}).

Antibiotic susceptibility tests using the Kirby-Bauer method showed that the level of resistance to meropenem, gentamicin, amikacin, imipenem, tobramycin, tetracycline, piperacillin-tazobactam, cefepime, ceftriaxone, ampicillin-sulbactam and polymyxin B was 69%, 82%, 63%, 74%, 56%, 51%, 70%, 97%, 95%, 49%, 3% ([Table 2](#t2-mjhid-10-1-e2018044){ref-type="table"}).

All 100 isolates of the main outbreak strains of A. baumannii were PCR positive for *blaOXA-51-like* genes.

Molecular distribution of aminoglycoside resistance genes including *aac(3)-IIa* and *aac(6′)- Ib* were 45% and 50%, respectively is shown in the [figure 1A and B](#f1-mjhid-10-1-e2018044){ref-type="fig"}. Half of the isolates (50%) contained the *qnrA* ([Figure 1C](#f1-mjhid-10-1-e2018044){ref-type="fig"}). *QnrB* and *qnrS* were not found in any strains. Sequencing of PCR products for AME and PMQR genes were confirmed by BLAST at NCBI.

Discussion
==========

Drug resistance in *A. baumannii* has become a global problem for the severely infected patients who critically rely on Antimicrobial therapy. The emergence of clinical *A. baumannii* strains with different antibiotic resistance phenotypes causes difficulties in treating infections caused by this organism.[@b19-mjhid-10-1-e2018044],[@b20-mjhid-10-1-e2018044]

Multidrug-resistant *A. baumannii* (MDR-Ab) is a subject of profound anxiety as it not only causes severe and fatal infections but also increases the length of hospital stay, resulting in augmented treatment charges.[@b21-mjhid-10-1-e2018044]

In this study, the most antibiotic resistance in *A. baumannii* isolates were related to cefepime (97%), ceftriaxone (95%), and amikacin (82%), and the most effective drug against these isolates was polymyxin B. This data is also valid for colistin, which is mostly used in clinics worldwide.

Henwood et al.,[@b22-mjhid-10-1-e2018044] showed that more than 75% of *A.baumannii* strains were resistant to cefotaxime and ceftazidime. In another study, Karlowsky et al.,[@b23-mjhid-10-1-e2018044] showed that \>90% of *A. baumannii* isolates were susceptible to imipenem and meropenem; fewer strains were susceptible to amikacin, and \<60% were susceptible to ceftazidime and gentamicin.

In agreement with the current study, polymyxins, are active agents against the overwhelming majority of *A. baumannii* throughout the world. In a systematic review study directed by Razavi Nikoo et al.,[@b24-mjhid-10-1-e2018044] polymyxins presented adequate activity against *A. baumannii* collected. The frequencies of MDR and XDR isolates were 70% and 19% respectively. No PDR isolates were identified in this study.

Hujer et al.[@b25-mjhid-10-1-e2018044] in their study reported that 89% of *A. baumannii* were resistant to at least three different classes of antibiotics, and 15% were resistant to all antibiotics tested.

Aminoglycosides are used most commonly in the treatment of *A. baumannii* infections. Most enzyme-mediated resistance in *A. baumannii* is due to AMEs encoded genes which found on the mobile genetic elements.

PMQR genes including *qnrA, qnrB,* and *qnrS* are responsible for quinolone resistance in *A. baumannii* which the prevalence of quinolone-resistant *A. baumannii* was increased in recent years. In our study, the prevalence rate of PMQR genes including *qnrA, qnrB,* and *qnrS* was 50%, 0%, and 0%, respectively. In contrast with our data, Chagas et al.,[@b26-mjhid-10-1-e2018044] showed that the prevalence of *qnrA* gene was 37.5% (n=15). The differences mentioned above can result from the geographical distance, surveillance strategies, and restraint in antibiotic prescriptions in other regions.

Conclusions
===========

This study showed that the most effective antibiotic against clinical strains of *A. baumannii* was polymyxin B and we recommend clinicians to use polymyxins (B or E) in patients infected with MDR *A. baumannii.* However*,* overusing can lead to polymyxin resistance, and the drug's toxicity problems should be considered. There is a high level of aminoglycoside resistance genes among *A. baumannii* isolates circulating in hospitals in Iran. This trend of MDR profiles associated with the presence of *aac(6′)-Ib* and *aac(3)-IIa* genes are worrying. The high prevalence rate of these resistance genes highlights the necessity for establishing more rapid diagnostic assays, more antimicrobial susceptibility tests, more clinician-laboratory correlation, and continuous monitoring of antibiotic resistance due to *A. baumannii*.
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![**A)** *PCR amplification of the aac(3)-IIa gene.* Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (740bp); lane 1, 6, and 7: negative results and lane 2, 3, 4, and 5: positive results. **B)** *PCR amplification of the aac(6′)-Ib gene.* Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (482bp); lane 1--7: positive results. **C)** *PCR amplification of the qnrA gene.* Lane M: Ladder (100 bp), lane Cont-: negative control, lane Cont+: positive control (649bp); lane 1--4, 5, and 7: positive results, lane 5: negative result.](mjhid-10-1-e2018044f1){#f1-mjhid-10-1-e2018044}

###### 

PCR primers and annealing temperatures used in this study.

  Target genes       Forward                   Reverse                 Annealing (°C)   Amplicon size (bp)
  ------------------ ------------------------- ----------------------- ---------------- --------------------
  ***qnrA***         ATTTCTCACGCCAGGATTTG      GATCGGCAAAGGTTAGGTCA    58               649
  ***qnrB***         GGCTCGAAATTCGCCACTG       TTTGCTGTTCGCCAGTCGAA    52               469
  ***qnrS***         GCA AGTTCATTGAACAGGGT     TCTAAACCGTCGAGTTCGGCG   50               428
  ***aac(3)-IIa***   CGGAAGGCAATAACGGAG        TCGAACAGGTAGCACTGAG     58               740
  ***aac(6′)-Ib***   TTGCGATGCTCTATGAGTGGCTA   CTCGAATGCCTGGCGTGTTT    55               611

###### 

Antibiotics resistance profile among *A.* baumannii isolates.

  -------------------------------------------------------------------
  Antibiotic                Resistant\   Intermediate\   Sensitive\
                            No (%)       No (%)          No (%)
  ------------------------- ------------ --------------- ------------
  Meropenem                 69(69%)      16(16%)         15(15%)

  Gentamicin                82(80.4%)    6(5.9%)         14(13.7%)

  Amikacin                  63(63%)      10(10%)         27(27%)

  Imipenem                  74(76%)      14(14%)         10(10%)

  Tobramycin                56(56%)      7(7%)           37(37%)

  Tetracycline              51(51%)      14(14%)         35(35%)

  Piperacillin-Tazobactam   70(70%)      0(0%)           30(30%)

  Cefepime                  97(97%)      1(1%)           2(2%)

  Ceftriaxone               95(95%)      5(5%)           0 (0%)

  Ampicillin-Sulbactam      49(49%)      17(17%)         34(34%)

  Polymyxin B               3(3%)        (0%)            97(97%)
  -------------------------------------------------------------------
